載入...
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
BACKGROUND AND OBJECTIVES: Risankizumab is a humanized anti-interleukin-23 monoclonal antibody in development for the treatment of several inflammatory diseases. This work characterized the pharmacokinetics of risankizumab and evaluated covariates that may affect its exposures using phase I and II t...
Na minha lista:
| 發表在: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6373392/ https://ncbi.nlm.nih.gov/pubmed/30123942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0704-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|